litronesib

Litronesib is a small molecule, investigational anticancer drug that acts as a selective inhibitor of the mitosis-specific kinesin motor protein Eg5 (also known as KIF11 or kinesin spindle protein). By inhibiting Eg5, litronesib disrupts the formation of bipolar spindles during mitosis, leading to mitotic arrest and subsequent apoptosis in actively dividing tumor cells. This mechanism targets cancer cell proliferation with reduced effects on non-dividing cells. Litronesib was developed by Kyowa Hakko and Eli Lilly and Company for the treatment of various solid tumors and hematologic malignancies, including ovarian cancer, gastric cancer, prostate cancer, acute leukemia, breast cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer (NSCLC), esophageal cancer, small cell lung cancer (SCLC), and other solid tumors. Clinical development reached up to phase II trials but has since been discontinued for all indications[2][3][4][7].

Other names

litronesib